natgillin/translations-raw huggingface dataset:
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 25, wherein the one or more further therapeutic agents are selected from the group consisting of cisplatin, gefitinib, cetuximab, rituximab, bevacizumab, erlotinib, bortezomib, thalidomide, pamidronate, zoledronic acid, clodronate, risendronate, ibandronate, etidronate, alendronate, tiludronate, arsenic trioxide, lenalidomide, filgrastim, pegfilgrastim, sargramostim, suberoylanilide hydroxamic acid, and SCIO-469. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 22, naznačena time što je jedno ili više daljnjih terapijskih sredstava odabrano iz skupino koja se sastoji od cisplatina, gefitiniba, cetuksimaba, rituksimaba, bevacizumaba, erlotiniba, bortezomiba, talidomida, pamidronata, zoledronske kiseline, klodronata, porandronata, ibandronata, etidronata, alendronata, tiludronata, arsenovog trioksida, lenalidomida, filgrastima, pegfilgrastima, sargramostima, suberoilanilid- hidroksamične kiseline i SCIO-469.
Pharmacokinetics of Anti-PD-1 Antibody (BMS-936558) 
(b) dozu anti-PD-1 antitijela koje sadrži
LC/MS = high performace liquid chromatography and mass spectrometry 
LC/MS = tekućinska kromatografija visoke učinkovitosti i masena spektrometrija MeOH
The compound of Claim 1 wherein R1 is selected from C1-6alkyl optionally substituted with hydroxy or methoxy, and tetrahydropyran. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da R1 je odabran od C1-6alkila po izboru susptituiranog s hidroksi ili metoksi i tetrahidropiranom.
The nucleic acid molecule of claim 1, wherein the VL domain and the VH domain are each linked to a utility peptide. 
Molekula nukleinske kiseline prema patentnom zahtjevu 1, naznačena time, da su VL i VH povezani s Fc, oznakom i/ili markerom.
The floor assembly of claim 8, wherein said heating member is one of a wire and a fluid conduit. 
Podni sklop u skladu s patentnim zahtjevom 6, naznačen time što je navedeni grijaći element (5) jedno od žice i cjevovoda za tekućinu.
The single use or multiple use formulated product or composition may further comprise a salt comprising a pharmaceutically acceptable alkali metal cation selected from the group consisting of Na+- or K+-salts, or a combination thereof. Preferably the salt is a Na+-salt, for example NaCl or Na2SO4. 
Proizvod, koji sadrži rekombinantni folikulostimulirajući hormon (FSH) dobiven iz ljudske stanične linije za uporabu kod liječenja neplodnosti prema bilo kojem prethodnom zahtjevu, naznačen time da proizvod nadalje sadrži sol, koja sadrži farmaceutski prihvatljiv kation alkalijskog metala, koji je izabran iz skupine, koja sadrži Na*-ili K*- soli ili njihovu kombinaciju.
a sensor (12) which detects the level of the coffee being cooked, 
- > senzor (12) koji otkriva razinu kave koja se kuha,
The hinge according to claim 7, characterised in that a further semicircular groove (35a) is formed on said sleeve (29), symmetrically located with respect to said semicircular groove (35) in relation to a vertical plane passing through the sleeve axis. 
Šarka u skladu s patentnim zahtjevom 6, naznačena time, da se na navedenoj navlaci (29) dodatno formira polukružni utor (35a), simetrično postavljen u odnosu na navedeni polukružni utor (35) u odnosu na vertikalnu ravninu koja prolazi kroz os navlake.
proximity of the deleted region of SfNIC-C 
Datum podnošenja europske prijave patenta:
The polypeptide according to claim 7, wherein the toxin is Pseudomonas exotoxin or a biologically active variant thereof. 
Polipeptid u skladu s patentnim zahtjevom 7, naznačen time što toksin je egzotoksin iz bakterije roda Pseudomonas ili njegova biološki aktivna varijanta.
The level of formula (II) in solution was monitored over time, by withdrawing a small sample of the fluid and comparing its LC-MS response to that of a matrix-matched external standard (i.e. 
Razina spoja formule (II) u otopini se prati tijekom vremena, povlačenjem malog uzorka tekućine i uspoređivanjem njegovog LC-MS odgovora s onim matriksnog vanjskog standarda (tj.
reacting the amines 2 and 3, in mixture, with the pair of epoxides 4 and 5, in mixture, to obtain a mixture of four compounds (6, 7, 8 and 9); 
reagiranja amina 2 i 3, u smjesi s parom epoksida 4 i 5, u smjesi, kako bi se dobila smjesa od četiri spoja (6, 7, 8 i 9);
Other particular examples of the compounds of Formula I are compounds of the Formula ID: wherein: 
Drugi konkretni primjeri spojeva prikazanih Formulom I jesu spojevi prikazani Formulom ID: u kojima:
The process as claimed in claim 1, wherein said at least one mineral acid is hydrochloric acid. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7-8, naznačen time što je navedena najmanje jedna mineralna kiselina klorovodična kiselina.
The compound or composition for use of claim 3, wherein the disease or disorder is prostate cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je genitalno-urinarni rak.
The method of claim 2, wherein R41 is selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R4, izabran iz skupine koju čine -H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi 1 ciklopropoksi.
The coating material as recited in claim 1, wherein the hydroxy-functional binder component comprises from 5 to 40 wt % of the inorganic pigment based on a total weight of the hydroxy-functional binder component. The coating material as recited in claim 2, wherein, 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da vezivna komponenta sadrži od 5 do 40 masenih % anorganskih punila i/ili anorganskih pigmenata bazi ukupne mase vezivne komponente.
and wherein all aryl-, cycloalkyl-, cyclic amide, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1, R1', R1" and R3 to R10 may be unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, =O, halogen, C1-6-alkyl, phenyl, C1-6-alkyl substituted by halogen or C1-6-alkoxy; 
i gdje svaki aril-, cikloalkil-, ciklički amid, heterocikloalkil ili heteroarilne skupine s 5 ili 6 članova kao što je definirano za R1, R1’, R1" i R3 do R10 mogu biti nesupstituirani ili supstituirani s jednim ili više supstituenata izabranih iz skupine koja se sastoji od hidroksi, =O, halogen, C1-6-alkil, fenil, C1-6-alkil supstituiran halogenom ili C1-6-alkoksi;
The rAAV particle of claim 5, wherein the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin or wherein the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin. 
Čestica rAAV prema patentnom zahtjevu 5, naznačena time što nukleinska kiselina koja kodira miR-708 je 5' prema nukleinskoj kiselini koja kodira rodopsin ili pri čemu nukleinska kiselina koja kodira miR-708 je 3' prema nukleinskoj kiselini koja kodira rodopsin.
FIG. 11: Direct binding ELISA of the pre-candidate pool antibodies to recombinant human Nogo-A (GST-Nogo-A 5+6). 
Slika 9: ELISA uz izravno vezanje protutijela iz fonda predkandidata s rekombinantnim ljudskim Nogo-A (GST-Nogo-A 5+6).
filtering the crystal, then washing and drying the filtered crystal. The crystal according to claim 9, wherein the crystallization solvent is a mixed solvent of ethanol/water. A crystal of the compound of claim 1 prepared by a method comprising: 
filtriranje kristala, zatim ispiranje i sušenje. Postupak za pripremanje kristalnog oblika i spoja formule (I) sukladno zahtjevima 2 ili 3, koji sadrži slijedeće korake:
24, and a L-CDR3 sequence which is 78% or more identical to the L-CDR3 sequence shown in SEQ ID NO. 
24,1 (vi) slijed L-CDR3, koji je 78% ili više istovjetan slijedu L-CDR3 prikazanom u SEQ ID NO.
as a second component, at least one free mRNA encoding at least one antigen wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal and wherein the use comprises administering the composition to a patient in need thereof in a safe and effective amount. 
kao druge komponente, barem jedne slobodne mRNK koja kodira barem jedan antigen pri čemu imunostimulacijski pripravak je u stanju izazvati ili poboljšati prirođeni i proizvoljno prilagodljiv imunološki odgovor kod sisavca i pri čemu primjena obuhvaća davanje pripravka pacijentu kojem je to potrebno u sigurnoj i učinkovitoj količini.
The device of claim 1, wherein the adhesive is an epoxy material. 
Uređaj prema zahtjevu 1, naznačen time da ljepilo je epoksi materijal.
The water-based herbicidal suspension according to Claim 4, wherein the inorganic salt is sodium dihydrogenphosphate. 
Herbicidna suspenzija na bazi vode u skladu s patentnim zahtjevom 4, naznačena time, da je anorganska sol natrijev dihidrogenfosfat.
Pharmaceutical composition containing at least one crystalline form of cortexolone-17a-propionate in association with at least one physiologically acceptable excipient, wherein said at least one crystalline form of cortexolone-17a-propionate is selected from: crystalline form I characterised by a DRX as represented in Figure 1 and by a DSC as represented in Figure 2 and by an IR spectrum as represented in Figure 3; crystalline form III characterised by a DRX spectrum as represented in Figure 7 or 10 or 13 and by a DSC spectrum as represented in Figure 8 or 11 or 14 and by an IR spectrum as represented in Figure 9 or 12 or 15; hydrate crystalline form IV characterized by a DRX spectrum as represented in Figure 28. 
PATENTNI ZAHTJEVI M» Farmaceutski pripravak koji sadrži najmanje jedan kristalni oblik korteksolon-17a-propionata u vezi sa najmanje jednim fiziološki prihvatljivim ekscipijensom, gdje navedeni najmanje jedan kristalni oblik korteksolon-17a- propionata je odabran od: kristalnog oblika I okarakterizirano pomoću DRX kao što je prikazano na slici 11 DSC kao što je prikazano na slici 2 i IR spektra kao što je prikazano na slici 3; kristalnog oblika III okarakterizirano pomoću DRX spektra kao što je prikazano na slici 7 ili 10 ili 13 1 DSC spektra kao što je prikazano na slici 8 ili 11 ili 141 IR spektra kao što je prikazano na slici 9 ili 12 ili 15; hidratnog kristalnog oblika IV okarakterizirano pomoću DRX spektra kao što je prikazano na slici 28.
The use of claim 16, wherein the pathological conditions are selected from the group consisting of inflammatory disease, autoimmune disease, systemic inflammatory response syndrome, reperfusion injury after organ transplantation, cardiovascular affections, obstetric and gynecologic disease, infectious (viral and bacterial) disease, allergic and atopic disease, solid and liquid tumor pathologies, transplant rejection diseases, congenital diseases, dermatological diseases, neurological diseases, cachexia, renal diseases, iatrogenic intoxication conditions, metabolic and idiopathic diseases, and ophthalmological diseases. 
Uporaba iz zahtjeva 16, naznačena time, što su patološka stanja odabrana iz grupe koja se sastoji od upalnih oboljenja, autoimunih oboljenja, sindroma sustavnog upalnog odgovora, reperfuzione povrede poslije transplantacije organa, kardiovaskularnih poremećaja, oboljenja u opstetrici i ginekologiji, infektivnih (virusnih i bakterijskih) bolesti, alergijskih 1 atopijskih bolesti, patologija solidnih i tekućih tumora, bolesti odbacivanja transplantata, kongenitalnih bolesti, dermatoloških bolesti, neuroloških bolesti, kaheksije, bubrežnih bolesti, stanja jatrogene intoksikacije, metaboličkih i idiopatskih bolesti i oftalmoloških oboljenja.
Controller 80 can operate on 12 VDC. 
Kontrolor 80 može raditi na 12 V istosmjerne struje.
providing the closure with a top casing, enveloping those parts of the primary vessel that are not already surrounded by the bottom casing or top casing with a film, the film extending from the bottom casing to the top casing and connecting them to each other. 
omatanje s folijom onih dijelova primarne posude koji već nisu okruženi s dnom kućišta ili vrhom kućišta, te se folija pruža od dna kućišta do vrha kućišta i međusobno ih povezuje.
Since the aspiration also involves the third suction cup 5, the latter adheres to said second external lateral face of the container. 
Budući da usisavanje također uključuje i treću usisnu čašicu 5, ova posljednja se pričvrsti na navedenu drugu vanjsku bočnu plohu spremnika.
In a further preferred embodiment of the present invention, subunits (X) and (Y) are in each case arranged in layers relative to one another. 
U daljnjem pogodnom obliku izvedbe predmetnog izuma podjedinice (X) i (Y) su uvijek oblikovane u slojevima, smještenim jedan prema drugom.
A method for producing an isolated IL-23p19 antibody according to claim 1 or claim 2, comprising providing a host cell or non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody. 
Postupak in vitro za proizvodnju izoliranog IL-23p19 antitijela prema bilo kojem od patentnih zahtjeva 1-7 1 10-14, naznačen time da osigurava stanicu domaćina ili neljudske transgene životinje ili transgene biljke ili biljne stanice pogodne za expresiju nadoknadive količine spomenutog antitijela.
The method of claim 1 or 2, wherein insulin glargine or/and a pharmaceutically acceptable salt thereof is administered subcutaneously. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se inzulin glargin ili/i njegova farmaceutski prihvatljiva sol primjenjuje potkožno.
Use according to claims 1 to 4 wherein the composition is up to 83% protective in a population of vaccinated individuals against severe gastro-enteritis caused by infection of rotaviruses of at least two non-G1 serotypes. 
Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti do 83% u populaciji osoba cijepljenih protiv teškog gastroenteritisa uzrokovanog infekcijom rotavirusima iz najmanje dva ne-G1 serotipa, koje se bira iz skupine koju čine G2, G3, G4 i G9.
A kit according to claim 10, characterised in that the reservoir essentially consists of an elastomer and an active agent. 
Set prema zahtjevu 10, naznačen time što spremnik u biti sadrži elastomer i djelatnu tvar.
F, G, H, K and L are, independently, selected from the group consisting of hydrogen, halogen, cyano, C1-4 alkyl, halosubstituted C1-4 alkyl, hydoxysubstituted C1-4 alkyl, and C1-4 alkoxy; 
S G F, G, H, Ki L se neovisno bira iz skupine koju čine vodik, halogen, C1-4 alkil, halogenom supstituirani C1-4 alkil, hidroksi supstituirani C1-4 alkil i C1-4 alkoksi;
The formulation of anti-TFPI antibody used in this Example contained 10 mM acetate buffer, 88 mM sucrose, and 200 ppm Tween 80. NaCl concentrations were varied from 0 mM to 300 mM. 
Formulacija anti-TFPI protutijela, koja sadrži: 10 mM do 30 mM histidina, 50 ppm do 200 ppm neionskog surfaktanta, 88 mM do 292 mM saharoze,
treating the solution with a strong, sterically hindered base to form the boron “ate” complex of formula (II). 
(b) tretman otopine iz koraka (a) jakom, prostorno spriječenom bazom da bi se formirao kompleks borata formule
Consequently, the combinations of the invention possess therapeutically advantageous properties, which make them particularly suitable for the treatment of respiratory diseases in all kind of patients, including those having an underlying heart condition. 
Prema tome, kombinacije sukladno predmetnom izumu posjeduju terapijski povoljne osobine, koje ih čine osobito prikladnim za liječenje respiratornih bolesti kod svih vrsta bolesnika.
A process according to claims 1 or 6, wherein compound (I'-a) is obtained by reacting equimolar amounts of bromine and a compound of formula (I'-c), at 0-5°C in DCM: 
Postupak prema zahtjevima 1 ili 6, gdje se spoj (T'-a) dobiva reakcijom ekvimolarnih količina broma 1 spoja formule (T'-c), na 0-5%€ u DCM-u:
Corresponding hot substance drugs are known per se to the person skilled in the art and are described, for example, in “Pharmazeutische Biologie—Drogen and ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd., revised edition, Gustav Fischer Verlag, Stuttgart-New York, 1982, pages 82 et seq. 
Odgovarajuće nadražujuće droge su poznate stručnjaku i opisuju se primjerice u "Pharmazeutische Biologie - Drogen und Inhaltsstoffe" od prof. dr. Hildebert Wagner, 2., prerađeno izdanje, naklada Gustav Fischer, Stuttgart-New York, 1982, stranice 82 i daljnje.
Further examples of suitable softeners are, for example, multivalent alcohols as glycerol and 1,2-propanediol, as well as softeners such as levulinic acid and caprylic acid, which can also be esterified by polyethylene glycols. 
Dalji primjeri prikladnih omekšivača su, na primjer, viševalentni alkoholi kao što je glicerol i 1,2-propandiol, kao i omekšivači kao što je levulinska kiselina i kaprilna kiselina, koje se također mogu esterificirati pomoću polietilen glikola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families. 
polimeraza odabrana iz skupine koja se sastoji od virusnih polimeraza orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae; ili
The process of item 6, wherein the product is dried by means of lyophilisation. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se proizvod osuši liofiliziranjem.
Compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof for the stimulation of an opioid-receptor function in a cell for the treatment of pain or diarrhea. 
Spoj prema zahtjevu 1 ili 2 ili njegova farmaceutski prihvatljiva sol naznačen time da je za stimuliranje funkcije opioidnog-receptora u stanici, kod liječenja boli ili proljeva.
is aminopyridyl, in which aminopyridyl is unsubstituted or substituted independently of one another once, twice or three times by halogen or methyl, 
A2 je aminopiridil, gdje aminopiridil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran halogenom ili metilom,
As used herein, "BTDS" means "Buprenorphine Transdermal System", and "BTDS X", wherein "X" is a number higher than zero, means a transdermal dosage form containing X milligrams of buprenorphine. 
Kao što se ovdje koristi, "TSB" (engl.: "BTDS") označuje "transdermalni sustav buprenorfina", a "TSB X" (engl: "BTDS X"), pri čemu je "X" broj veći od nule, označuje transdermalni oblik doziranja koji sadrži X miligrama buprenorfina.
means for introducing sludge into the sludge drying bed, comprising a valve controlled inlet pipe; 
(d) element za uvođenje mulja u ležište za sušenje mulja (14), koji se sastoji od ventilom kontrolirane ulazne cijevi (9);
VL1-L1-VL2-L2-CL [I] and a second polypeptide chain has a structure represented by the formula: VH2-L3-VH1-L4-CH1 [II] wherein: 
[1] i drugi polipeptidni lanac ima strukturu predstavljenu s formulom: Vin-La-Vry-L4-Cru [II] pri čemu:
The use of claim 4, wherein said antibody specifically binds a cancer antigen associated with a cancer, optionally wherein said cancer is either (i) breast, ovarian, prostate, cervical, lung or pancreatic cancer; or (ii) breast cancer and said antigen is HER2/neu. 
Upotreba u skladu s patentnim zahtjevom 4, naznačena time što se navedeno protutijelo specifično veže na kancerozni antigen povezan s rakom, gdje navedeni može biti bilo (i) rak dojke, jajnika, prostate, vrata maternice, pluća ili gušterače; ili (1i) rak dojke, gdje je navedeni antigen HER2/neu.
The method as defined in claim 7, wherein when the magnitude relationship as a result of the comparison in the comparator exceeds the predetermined value, the counted value is controllably discarded. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što dodatno uključuje korak upravljivog odbacivanja izbrojane vrijednosti, kada odnos veličina kao rezultat usporedbe u komparatoru premašuje zadanu vrijednost.
A method of treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1 which comprises administering to a subject a therapeutically effective amount of a compound according to claim 1 or 2 or 20. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-a i IL-1.
The method of any one of claims 1-10, wherein the aqueous particle composition to which the PVA is added is free of PVA. 
Postupak prema bilo kojem od zahtjeva 1-4, pri čemu je vodeni sastav čestica u koji je dodan polivinil alkohol slobodan od polivinil alkohola.
The seat (32) of the collar is shaped as a “C” and disposed above the annular flange (30). 
(31) Broj prve prijave: AN20120088 (32) Datum podnošenja prve prijave: 12.07.2012.
adding a solution of FeCl3 to the solution of (ii) at a temperature within the range of from 10 to 30°C; 
dodavanje otopine FeCl3 otopini u skladu s korakom (ii) temperature unutar raspona od 10 do 30°C; količina FeCl3 raspona od 30% masenog udjela do 120% masenog udjela količine glukoznog sirupa.
In summary, the GnRH receptor antagonists of this invention may be assayed by the general methods disclosed above, while the following Examples disclose the synthesis of representative compounds of this invention. 
Ukratko, antagoniste receptora GnRH prema ovom izumu može se ispitati općim postupcima, opisanim gore, dok sljedeći Primjeri opisuju sintezu reprezentativnih spojeva prema ovom izumu.
Preferred salts of risperidone or paliperidone include those having a water solubility of less than or about 2 mg/ml. 
Sastav u skladu s jednim od prethodnih zahtjeva, pri čemu je topivost lijeka u otapalu manja od 90 mg/ml.
A succinate salt of formula II: 
Sukcinat formule II ili hidrat te soli:
The pistol according to claim 1, wherein said locking block comprises a fiber-reinforced aramid including glass fibers. 
Pištolj prema zahtjevu 1, naznačen time, da blok za zaključavanje (8) sadrži ojačano vlakno, poželjno ojačano stakleno vlakno, aramid.
Preferably, the tablet comprises magnesium stearate as lubricant. 
Poželjno, tableta sadržava magnezij stearat kao sredstvo za podmazivanje.
Method for treating water at low cost, wherein the method purifies the water and eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the method comprising: 
Metoda za tretiranje vode niskih troškova te za korištenje nizvodno od industrijskog postupka (2), koja pročišćava vodu i uklanja otopljene čvrste čestice u vodi filtriranjem male frakcije ukupnog volumena vode, metoda obuhvaća:
A method according to claim 1 or claim 2 further comprising applying a second polymeric layer over the composite layer. 
Postupak sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2 nadalje obuhvaća nanošenje drugog polimernog sloja preko kompozitnog sloja.
Some illustrative examples of such cycloalkenyl groups are cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. 
Neki tipični primjeri takvih cikloalkenilnih skupina su ciklopentenil, cikloheksenil, cikloheptenil i ciklooktenil.